Amit Singal, M.D.

Download Curriculum Vitae

Amit Singal, M.D., M.S., has had several patients who were cured of liver cancer, but he would like to have many more.

A hepatologist, Dr. Singal treats patients with liver disease and cares for transplant recipients pre- and post-surgery. He is an Associate Professor of Internal Medicine in the Division of Digestive and Liver Diseases at UT Southwestern Medical Center. He is Medical Director of the UT Southwestern Liver Tumor Program and Clinical Chief of Hepatology.

Most of Dr. Singal’s research examines how to diagnose and treat liver cancer before it becomes incurable. Unfortunately, he says, too many patients are diagnosed when their cancer is already in the advanced stages.

“If we diagnose liver cancer at an early stage, we can often cure it,” Dr. Singal says. “Patients can live over five years if we diagnose and treat liver cancer early. However, when it’s found at a late stage, the average survival is typically less than one year.”

Dr. Singal is a native of the Detroit area and completed most of his medical education at the University of Michigan. He earned his medical degree and a Master of Science at the University of Michigan, as well as fellowships in gastroenterology and transplant hepatology. Dr. Singal completed his internal medicine residency at the University of Washington in Seattle.

Dr. Singal began his career at UT Southwestern in 2010. He was drawn to Texas and UT Southwestern because liver cancer is a particular problem in Texas, and he believes UT Southwestern is the best place to help do something about it.

“Texas has the second-highest incidence rate for liver cancer across the country,” Dr. Singal says. “Furthermore, it’s currently the fastest-growing cancer in Texas.”

Dr. Singal is doing everything he can to change that. He is working with primary care physicians and other hepatologists to better understand and follow guidelines for liver cancer screening. People with liver disease, who are at risk for liver cancer, should be screened every six months, but less than 20 percent of patients are currently having this done.

He’s also hopeful about new advances in medicine.

“We’ve made incredible strides in treatments for liver cancer already over the past decade. Over the next decade, we will see even more advances in therapeutic options for this cancer.”

Dr. Singal is board certified in internal medicine, gastroenterology, and transplant hepatology. He is also a member of the American Gastroenterology Association, the American College of Gastroenterology, the American Association for the Study of Liver Diseases, and the International Liver Cancer Association.

Dr. Singal has received numerous grants, including those from the National Institute of Health (NIH), Cancer Prevention Research Institute of Texas (CPRIT), and Department of Defense (DOD). His research has been published in many peer-reviewed publications, such as JAMA, Gastroenterology, Hepatology, Cancer Epidemiology Biomarkers & Prevention, and Clinical Gastroenterology and Hepatology. Dr. Singal also lectures frequently on liver cancer throughout the country.

In 2018, he was named a Super Doctor by Texas Monthly.

Personal Note

During his off time, Dr. Singal likes to travel internationally. And he loves to cheer on his home teams – the Michigan Wolverines, Detroit Lions, and Detroit Red Wings – when they are in Dallas.